Reduce the dose to 75% of the standard dose for CYP2D6 intermediate metabolizer (IM) patients with indications other than the diagnosis of Brugada syndrome and record an ECG and monitor the plasma concentration. This evidence concerns the gene CYP2D6 and Brugada syndrome.